Send us Fan Mail

Cobenfy doesn't block dopamine — and that's the whole point. In this special episode, we step away from the bipolar just a bit to unpack the first genuinely new mechanism in schizophrenia treatment in decades. We break down how Cobenfy pairs xanomeline (a brain-penetrant M1/M4 muscarinic agonist) with trospium (a peripheral blocker that curbs the side effects), trace its surprising betel-nut origins, and explain the why behind the how: quieting dopamine in the striatum for positive symptoms and boosting GABA in the prefrontal cortex for cognition — all without the D2 blockade that brings EPS, weight gain, and sedation.

https://www.nguyenindoubt.com/theyinpsych
https://feeds.buzzsprout.com/2185312.rss